Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 7Neuroendocrine Tumors 2Multiple Myeloma 2Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lymphoma 1Liver Cirrhosis 1Hepatitis C 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 3Pyridoxine 2Etoposide 2Epoetin Alfa 2Cisplatin 2Capecitabine 2uridine triacetate 1peginterferon alfa-2b 1pegaspargase 1Vincristine 1Pyridostigmine Bromide 1Prednisolone 1Paclitaxel 1Oxaliplatin 1Octreotide 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Laparoscopy 1Introns 1Hydrocortisone 1Gemcitabine 1Furosemide 1Fluorouracil 1Filgrastim 1Erythropoietin 1Duloxetine Hydrochloride 1Doxorubicin 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Drug-Related Side Effects and Adverse Reactions × Introns × Clear all
NCT00221702 2010-10-13

EADO

University Hospital, Bordeaux

Phase 3 Completed
898 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡